Literature DB >> 24201832

[Biotechnological therapies for the treatment of back pain: alternatives to corticosteroids].

C Moser1, H-J Thiel, D Grönemeyer.   

Abstract

In recent years, it is increasingly clear that back pain is not only caused by biomechanical problems. Currently, biologically-based local therapy concepts for the treatment of affected spinal regions as an alternative to the standard treatment with steroids are in development or in early stages of clinical application. The common features of these new therapies are to intervene in the regulation of homeostasis at various key points at the affected region and specifically to suppress or block catabolic influences as well as to provide with anti-inflammatory substances and growth factors. These include on one hand the genetically produced Biologicals such as TNF-α inhibitors and cytokine antagonists and on the other hand therapies with autologous blood preparations (Autologous Conditioned Serum [ACS], and Platelet Rich Plasma formulations [PRP]). This article presents the individual methods, gives an overview of developments and results of various studies and discusses current recommendations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24201832     DOI: 10.1007/s00132-013-2197-7

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  32 in total

1.  Adalimumab in severe and acute sciatica: a multicenter, randomized, double-blind, placebo-controlled trial.

Authors:  Stéphane Genevay; Sebastien Viatte; Axel Finckh; Pascal Zufferey; Federico Balagué; Cem Gabay
Journal:  Arthritis Rheum       Date:  2010-08

Review 2.  Platelet-rich plasma: a review of the science and possible clinical applications.

Authors:  Vishal Mehta
Journal:  Orthopedics       Date:  2010-02       Impact factor: 1.390

3.  The treatment of disc-herniation-induced sciatica with infliximab: one-year follow-up results of FIRST II, a randomized controlled trial.

Authors:  Timo Korhonen; Jaro Karppinen; Leena Paimela; Antti Malmivaara; Karl-August Lindgren; Chris Bowman; Anthony Hammond; Bruce Kirkham; Simo Järvinen; Jaakko Niinimäki; Nic Veeger; Marianne Haapea; Markus Torkki; Osmo Tervonen; Seppo Seitsalo; Heikki Hurri
Journal:  Spine (Phila Pa 1976)       Date:  2006-11-15       Impact factor: 3.468

4.  Direct application of the TNF-alpha inhibitor, etanercept, does not affect CGRP expression and phenotypic change of DRG neurons following application of nucleus pulposus onto injured sciatic nerves in rats.

Authors:  Masaki Norimoto; Seiji Ohtori; Masaomi Yamashita; Gen Inoue; Kazuyo Yamauchi; Takana Koshi; Munetaka Suzuki; Sumihisa Orita; Yawara Eguchi; Ai Sugiura; Nobuyasu Ochiai; Masashi Takaso; Kazuhisa Takahashi
Journal:  Spine (Phila Pa 1976)       Date:  2008-10-15       Impact factor: 3.468

5.  Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study.

Authors:  S Genevay; S Stingelin; C Gabay
Journal:  Ann Rheum Dis       Date:  2004-04-28       Impact factor: 19.103

6.  Randomized, double-blind, placebo-controlled, dose-response, and preclinical safety study of transforaminal epidural etanercept for the treatment of sciatica.

Authors:  Steven P Cohen; Nikolai Bogduk; Anthony Dragovich; Chester C Buckenmaier; Scott Griffith; Connie Kurihara; Jolynne Raymond; Philip J Richter; Necia Williams; Tony L Yaksh
Journal:  Anesthesiology       Date:  2009-05       Impact factor: 7.892

7.  Tumor necrosis factor alpha and nucleus-pulposus-induced nerve root injury.

Authors:  K Olmarker; K Larsson
Journal:  Spine (Phila Pa 1976)       Date:  1998-12-01       Impact factor: 3.468

8.  Tumor necrosis alpha-blocking agent (etanercept): a triple blind randomized controlled trial of its use in treatment of sciatica.

Authors:  Tosan Okoro; Suhayl I Tafazal; Stephen Longworth; Philip J Sell
Journal:  J Spinal Disord Tech       Date:  2010-02

9.  Proinflammatory cytokines stimulate the expression of nerve growth factor by human intervertebral disc cells.

Authors:  Yumiko Abe; Koji Akeda; Howard S An; Yasuchika Aoki; Rajeswari Pichika; Carol Muehleman; Tomoatsu Kimura; Koichi Masuda
Journal:  Spine (Phila Pa 1976)       Date:  2007-03-15       Impact factor: 3.468

10.  The production of anti-inflammatory cytokines in whole blood by physico-chemical induction.

Authors:  H Meijer; J Reinecke; C Becker; G Tholen; P Wehling
Journal:  Inflamm Res       Date:  2003-10       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.